Natco Pharma share news and announcements
NSE: NATCOPHARMBSE: 524816Pharmaceuticals & BiotechnologySmall Cap
Last close ₹791.85up ₹6.70 (0.85%)BSE ₹792.20
Share price at the NSE close on 23 Oct 2026. Previous close ₹785.15.
52-week range of traded prices to 23 Oct 2026
₹773.60Low, 22 Oct 2026₹1,226.80High, 12 May 2026
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies.
- ₹15,534 Cr380th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. The filing of 14 Aug 2026
- 13.6
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet.
- Shares changed
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.57%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it. The filing of 14 Aug 2026
- 13.6%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet. The filing of 14 Aug 2026
- 8.6%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026. The filing of 29 May 2026
- 0.08
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day.
- 5,69,53550.8% delivered
Natco Pharma analyst meets
77 filed, newest first. Page 2 of 2.
May 2022
Feb 2022
9 Feb · Analysts
Nov 2021
9 Nov · Analysts
Aug 2021
Jun 2021
Feb 2021
Nov 2020
Aug 2020
Jun 2020
Feb 2020
Nov 2019
Aug 2019
May 2019
Feb 2019
Nov 2018
Aug 2018
May 2018
Feb 2018
Oct 2017
Aug 2017
May 2017
Feb 2017
Nov 2016
Aug 2016
2 Aug · Analysts
Feb 2016